Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Stock market today: Dow, S&P 500, Nasdaq struggle for gains in last stretch of 2025

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq struggle for gains in last stretch of 2025 US stocks fell slightly on Tuesday, as Wall Street tried to regroup after a tech-led slide in the final stretch of 2025…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • He would acquire Molina if he had the funds

    80% confidence

  • Metals and mining stock tailwinds should continue in early 2026, and the sector should outperform again as a result

    80% confidence

  • Most participants judged that further downward adjustments to the target range for the federal funds rate would likely be appropriate if inflation declined over time as expected

    80% confidence

  • Molina has a clearer path to significant double-digit long-term growth than Apple

    80% confidence

  • We're in a metals war

    80% confidence

  • GridFree AI is able to provide power infrastructure within two years

    80% confidence

  • Here we have the best loss ratio, the best expense ratio, the best win rate, and the most conservative accounting in one insurer

    80% confidence

  • If federal budgetary actions push the market downward, Molina's shares, currently trading at around $172, could drop below $100, which would be a 'generational buy'

    80% confidence

  • A few participants judged that lowering the federal funds rate target range at this meeting was not justified because data received over the intermeeting period did not suggest any significant further weakening in the labor market

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq struggle for gains in last stretch of 2025 — Source | Via News | ViaNews EU